Viking advances four Phase 3 obesity trials, reports positive VK2735 maintenance data
Viking said its SUNRISE oral Phase 3 trials for VK2735 have begun alongside the ongoing VANQUISH subcutaneous studies, while a maintenance-dosing readout showed durable weight loss with less frequent dosing.
SEC filing